Responsiveness to an erythropoiesis-stimulating agent is correlated with body composition in patients undergoing chronic hemodialysis

Responsiveness to an erythropoiesis-stimulating agent is correlated with body composition in patients undergoing chronic hemodialysis

BackgroundResistance to erythropoiesis-stimulating agents (ESA) is associated with adverse outcomes in patients undergoing chronic hemodialysis. However, the impact of body composition on ESA response remains uncertain. This study retrospectively investigated whether there is an association between...

Full description

Bibliographic Details
Main Authors:	Hyang Yun Lee, Suk-Won Suh, Jin Ho Hwang, Jungho Shin
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-12-01
Series:	Frontiers in Nutrition
Subjects:	erythropoiesis-stimulating agent resistance body composition bioelectrical impedance analysis hemodialysis outcome
Online Access:	https://www.frontiersin.org/articles/10.3389/fnut.2022.1044895/full

Similar Items

A possible contributor to erythropoiesis-stimulating agents requirement in hemodialysis: Paraoxonase 1 activity
by: Mehmet Kürşat Derici, et al.
Published: (2021-07-01)

Comparison of Patient Survival According to Erythropoiesis-Stimulating Agent Type of Treatment in Maintenance Hemodialysis Patients
by: Seok Hui Kang, et al.
Published: (2023-01-01)

Regulation of platelet count by erythropoiesis-stimulating agents – iron axis in hemodialysis patients
by: Koike K, et al.
Published: (2016-03-01)

Association between Dipeptidyl Peptidase-4 Inhibitor Prescription and Erythropoiesis-Stimulating Agent Hyporesponsiveness in Hemodialysis Patients with Diabetes Mellitus
by: Takeshi Hasegawa, et al.
Published: (2021-04-01)

Effect of long period treatment with erythropoiesis stimulating agents on clinically and laboratory parameters in hemodialysis autosomal dominant polycystic kidney disease patients
by: Orăsan Olga Hilda, et al.
Published: (2017-10-01)

Role of circulating endothelial progenitors in responsiveness to erythropoiesis-stimulating agents in hemodialysis patients
by: Akira Ishimitsu, et al.
Published: (2021-10-01)

Zinc Supplementation Enhances the Hematopoietic Activity of Erythropoiesis-Stimulating Agents but Not Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitors
by: Akira Takahashi
Published: (2024-02-01)

Roxadustat alleviates the inflammatory status in patients receiving maintenance hemodialysis with erythropoiesis-stimulating agent resistance by increasing the short-chain fatty acids producing gut bacteria
by: Xiu-Nan Zhao, et al.
Published: (2023-07-01)

The Effect of Erythropoiesis-Stimulating Agents on Platelet Aggregation in Peritoneal Dialysis Patients
by: Serkan Bakırdöğen, et al.
Published: (2019-11-01)

Treatment of renal anemia: Erythropoiesis stimulating agents and beyond
by: Patrick Biggar, et al.
Published: (2017-09-01)

Usefulness of mid-week hemoglobin measurement for anemia management in patients undergoing hemodialysis: a retrospective cohort study
by: Soo Ya Bae, et al.
Published: (2019-08-01)

In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study
by: Ylenia Ingrasciotta, et al.
Published: (2019-09-01)

Erythropoiesis-Stimulating Agents in the Management of Anemia in Chronic Kidney Disease or Cancer: A Historical Perspective
by: Matti Aapro, et al.
Published: (2019-01-01)

Contemporary Practice of Anemia Treatment Among Dialysis Patients in the United States
by: Eric D. Weinhandl, et al.
Published: (2023-12-01)

Cancer, meta-analysis and reporting biases: the case of erythropoiesis-stimulating agents
by: Thomy Tonia, et al.
Published: (2013-05-01)

Changes in Metabolomic Profiles Induced by Switching from an Erythropoiesis-Stimulating Agent to a Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor in Hemodialysis Patients: A Pilot Study
by: Kimio Watanabe, et al.
Published: (2023-08-01)

Diagnostic evaluation and assessment of anemia in a patient with chronic kidney disease and gastrointestinal angioectasias undergoing hemodialysis
by: Karen Courville, et al.
Published: (2022-07-01)

Temporal Trends in Hemoglobin, Use of Erythropoiesis Stimulating Agents, and Major Clinical Outcomes in Incident Dialysis Patients in Canada
by: Mark Canney, et al.
Published: (2021-04-01)

Adverse events of iron and/or erythropoiesis-stimulating agent therapy in preoperatively anemic elective surgery patients: a systematic review
by: Jorien Laermans, et al.
Published: (2022-10-01)

High dose ESAs are associated with high iPTH levels in hemodialysis patients with end-stage kidney disease: a retrospective analysis
by: Lan eChen, et al.
Published: (2015-11-01)

An open-label, sequential, dose-finding study of peginesatide for the maintenance treatment of anemia in chronic hemodialysis patients
by: Besarab Anatole, et al.
Published: (2012-08-01)

Ferric Carboxymaltose and Erythropoiesis-Stimulating Agent Treatment Reduces the Rate of Blood Transfusion in Refractory Anemia
by: Antonio Gidaro, et al.
Published: (2022-08-01)

Oxidative Stress Parameters Can Predict the Response to Erythropoiesis-Stimulating Agents in Myelodysplastic Syndrome Patients
by: Ana Cristina Gonçalves, et al.
Published: (2021-06-01)

Anaemia and heart failure: is there still a role for erythropoiesis-stimulating agents?
by: Massimo Volpe, et al.
Published: (2017-04-01)

The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model
by: Louise Crathorne, et al.
Published: (2016-02-01)

Long-term body composition changes in patients undergoing hemodialysis: a single-center retrospective study
by: Yumi Seto, et al.
Published: (2022-11-01)

Quantitative systems pharmacology model of erythropoiesis to simulate therapies targeting anemia due to chronic kidney disease
by: Mrittika Roy, et al.
Published: (2023-12-01)

Lung Ultrasound Estimates the Overhydration and Benefits Blood Pressure Control in Normal or Mild Symptomatic Hemodialysis Patients
by: Trirattanapikul A, et al.
Published: (2022-12-01)

The Associations between Erythropoietic Response with Inflammation Markers and Perfluorinated Chemicals in Hemodialysis Patients
by: Wen-Sheng Liu, et al.
Published: (2023-02-01)

Body composition changes and its association with dyslipidemia in patients receiving hemodialysis
by: Priyadarsini Samanta, et al.
Published: (2021-04-01)

Different effects of granulocyte colony-stimulating factor and erythropoietin on erythropoiesis
by: Tzu-Lin Chen, et al.
Published: (2018-05-01)

Editorial: Stress erythropoiesis
by: Jaira Ferreira de Vasconcellos, et al.
Published: (2023-02-01)

Investigating the support mechanisms provided by macrophages in human erythropoiesis
by: Diez-Sevilla, I
Published: (2017)

How to select appropriate hemoglobin target levels on health-related quality of life and outcomes for patients with chronic kidney disease?
by: Filippo Salvati
Published: (2013-12-01)

Primitive and definitive erythropoiesis in mammals
by: James ePalis
Published: (2014-01-01)

Patogenetic correction of anemia with erythropoiesis-stimulating agents in lymphoproliferative disorders (literature review)
by: N. A. Romanenko, et al.
Published: (2014-07-01)

Patogenetic correction of anemia with erythropoiesis-stimulating agents in lymphoproliferative disorders (literature review)
by: N. A. Romanenko, et al.
Published: (2014-07-01)

Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in hemodialysis patients
by: Kristina Petrulienė, et al.
Published: (2017-01-01)

Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors vs. erythropoiesis-stimulating agents on iron metabolism in non-dialysis-dependent anemic patients with CKD: A network meta-analysis
by: Junlan Yang, et al.
Published: (2023-03-01)

Obesity may be erythropoietin dose-saving in hemodialysis patients
by: Ghada M. El-Kannishy, et al.
Published: (2018-06-01)